Moderate-to-strong ATP7A expression (G2 or G3) was observed in over 70% of pre-treatment tumours (Fig. 2i, left and 2j, left), although we could not evaluate subcellular localisation of ATP7A by using IHC unfortunately. Here, ATP7A is linked to neoplasm.